Adult HPV vaccination (27-45 years): who benefits, when to offer, and how to counsel

OBJECTIVES: The aim of the study was to translate major international recommendations and the current evidence base into a practical approach for counselling adults aged 27-45 years about human papillomavirus (HPV) vaccination. METHODS: We conducted a targeted narrative review of guidance from the World Health Organization, the European Centre for Disease Prevention and Control and US public health sources that frame HPV vaccination in mid-adults as shared clinical decision-making. We prioritised systematic reviews, randomised trials and recent evidence syntheses relevant to mid-adult vaccination and vaccination after cervical excisional treatment. RESULTS: Global and European guidance emphasises that the greatest population impact is achieved by high vaccination coverage before sexual debut and therefore does not support routine population-wide vaccination programmes for mid-adults. In contrast, US guidance supports shared clinical decision-making for adults aged 27-45 years because some individuals may still derive meaningful personal benefit, particularly those not adequately vaccinated who anticipate new sexual partners or belong to higher-exposure networks (e.g., men who have sex with men) or who are immunocompromised. Vaccine effectiveness is highest in individuals not previously exposed to vaccine HPV types; vaccination prevents new infections but does not treat established infection or existing HPV-related disease. Evidence on vaccination after cervical conisation is mixed: observational studies often suggest reduced recurrence, whereas randomised-trial-only syntheses do not show a consistent overall reduction in recurrence of high-grade lesions (high-grade squamous intraepithelial lesion) or cervical intraepithelial neoplasia. CONCLUSIONS: Adult HPV vaccination should be considered selectively and framed as prevention of future infections. A brief shared decision-making conversation focusing on anticipated future exposure, realistic benefits, dosing, and ongoing screening can support consistent practice. We provide a decision algorithm and practice scenarios to facilitate implementation.